BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Delft A, Humphreys IS, Brown A, Pfafferott K, Lucas M, Klenerman P, Lauer GM, Cox AL, Gaudieri S, Barnes E. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 2016;65:112-23. [PMID: 26092843 DOI: 10.1136/gutjnl-2014-308724] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Khalid R, Anwar MF, Raees MA, Naeem S, Abidi SH, Ali S. An in silico approach to analyze HCV genotype-specific binding-site variation and its effect on drug-protein interaction. Sci Rep 2020;10:20885. [PMID: 33257748 DOI: 10.1038/s41598-020-77720-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Gaudieri S, Lucas M. Innate and adaptive immunity shape circulating HCV strains. Nat Genet 2017;49:657-8. [PMID: 28442794 DOI: 10.1038/ng.3856] [Reference Citation Analysis]
3 Brown A, Halliday JS, Swadling L, Madden RG, Bendall R, Hunter JG, Maggs J, Simmonds P, Smith DB, Vine L, McLaughlin C, Collier J, Bonsall D, Jeffery K, Dunachie S, Klenerman P, Izopet J, Kamar N, Dalton HR, Barnes E. Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus. Hepatology 2016;64:1934-50. [PMID: 27631819 DOI: 10.1002/hep.28819] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
4 Xie Z, Li Y, Long L, Liang H, Cai W, Shen T. Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. BMC Infect Dis 2018;18:254. [PMID: 29866105 DOI: 10.1186/s12879-018-3153-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Donnison T, Chinnakannan S, Cicconi P, Barnes E. Hepatitis C vaccines: how close are we to the promised land? In: Foster GR, Reddy KR, editors. Clinical Dilemmas in Viral Liver Disease. Wiley; 2020. pp. 208-15. [DOI: 10.1002/9781119533481.ch36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Smith DA, Fernandez-Antunez C, Magri A, Bowden R, Chaturvedi N, Fellay J, McLauchlan J, Foster GR, Irving WL, Simmonds P, Pedergnana V, Ramirez S, Bukh J, Barnes E, Ansari MA; STOP-HCV Consortium. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nat Commun 2021;12:6105. [PMID: 34671027 DOI: 10.1038/s41467-021-25649-6] [Reference Citation Analysis]
7 von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine 2018;36:313-21. [PMID: 29203182 DOI: 10.1016/j.vaccine.2017.10.079] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
8 Major ME. Hepatitis C: new clues to better vaccines? Gut 2016;65:4-5. [PMID: 26092844 DOI: 10.1136/gutjnl-2015-309829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
10 Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci 2020;21:E5644. [PMID: 32781731 DOI: 10.3390/ijms21165644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
12 Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep 2019;9:9251. [PMID: 31239471 DOI: 10.1038/s41598-019-45461-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
13 Kwon YC, Meyer K, Peng G, Chatterjee S, Hoft DF, Ray R. Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages. Hepatology. 2018; Epub ahead of print. [PMID: 29443378 DOI: 10.1002/hep.29843] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
14 Keoshkerian E, Hunter M, Cameron B, Nguyen N, Sugden P, Bull R, Zekry A, Maher L, Seddiki N, Zaunders J, Kelleher A, Lloyd AR; HITS-p and HITS-c investigators. Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection. J Viral Hepat 2016;23:985-93. [PMID: 27558465 DOI: 10.1111/jvh.12576] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
15 Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V; STOP-HCV Consortium. Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. Elife 2019;8:e42463. [PMID: 31478835 DOI: 10.7554/eLife.42463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ray RB, Ray R. Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship. Hepatology. 2019;69:889-900. [PMID: 30102776 DOI: 10.1002/hep.30214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
17 Duncan JD, Urbanowicz RA, Tarr AW, Ball JK. Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines (Basel) 2020;8:E90. [PMID: 32079254 DOI: 10.3390/vaccines8010090] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
18 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
19 Walker A, Skibbe K, Steinmann E, Pfaender S, Kuntzen T, Megger DA, Groten S, Sitek B, Lauer GM, Kim AY, Pietschmann T, Allen TM, Timm J. Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. J Virol 2016;90:33-42. [PMID: 26446603 DOI: 10.1128/JVI.01993-15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
20 Wijesundara DK, Gummow J, Li Y, Yu W, Quah BJ, Ranasinghe C, Torresi J, Gowans EJ, Grubor-Bauk B. Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice. J Virol 2018;92:e02133-17. [PMID: 29437963 DOI: 10.1128/JVI.02133-17] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
21 Luxenburger H, Graß F, Baermann J, Boettler T, Marget M, Emmerich F, Panning M, Thimme R, Nitschke K, Neumann-Haefelin C. Differential virus-specific CD8+ T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4. J Viral Hepat 2018;25:779-90. [PMID: 29397015 DOI: 10.1111/jvh.12874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
23 Bankwitz D, Krey T, Pietschmann T. [Development approaches for vaccines against hepatitis C virus infections]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35015104 DOI: 10.1007/s00103-021-03477-9] [Reference Citation Analysis]
24 Mekonnen ZA, Grubor-Bauk B, English K, Leung P, Masavuli MG, Shrestha AC, Bertolino P, Bowen DG, Lloyd AR, Gowans EJ, Wijesundara DK. Single-Dose Vaccination with a Hepatotropic Adeno-associated Virus Efficiently Localizes T Cell Immunity in the Liver with the Potential To Confer Rapid Protection against Hepatitis C Virus. J Virol 2019;93:e00202-19. [PMID: 31292249 DOI: 10.1128/JVI.00202-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
25 Rodrigo C, Leung P, Lloyd AR, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Eltahla AA; InC3 Collaborative. Genomic variability of within-host hepatitis C variants in acute infection. J Viral Hepat 2019;26:476-84. [PMID: 30578702 DOI: 10.1111/jvh.13051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]